CMX304: A phase 3, Open-Label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated Adenovirus Disease


Infectious Diseases : adenovirus


The purpose of this study is to determine whether Brincidofovir (or BCV for short) is a safe and effective treatment for adenovirus. BCVis being made available through this study as an experimental option for the treatment of adenovirus infection.

BCV is a modified form of an approved antiviral drug called cidofovir (or Vistide). BCV is taken by mouth and converted into cidofovir inside the body. Cidofovir isused for the treatment of adenovirus. Cidofovir works by blocking the virus from multiplying inside the body. However, cidofovir is very toxic to kidneys. Although BCV is converted to cidofovir inside the body, since BCV is a different form of cidofovir, it may be less toxic to kidneys, although this cannot be guaranteed.


Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Gabriela Marón, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.